Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung CancerRUDIN, Charles M; HANN, Christine L; RANSON, Malcolm R et al.Clinical cancer research (Print). 2012, Vol 18, Num 11, pp 3163-3169, issn 1078-0432, 7 p.Article

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid TumorsGANDHI, Leena; CAMIDGE, D. Ross; DIVE, Caroline et al.Journal of clinical oncology. 2011, Vol 29, Num 7, pp 909-916, issn 0732-183X, 8 p.Article